Characterization of neutralizing affinity-matured human respiratory syncytial virus F binding antibodies in the sub-picomolar affinity range

Journal of Molecular Recognition

Volumn 25, Issue 3, 2012, Pages 136-146

  Canziani, Gabriela A ^a,b   Melero, Jose A ^c   Lacy, Eilyn R ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b In Silico Molecular LLC   (United States)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

affinity; avidity; Biacore; Fab; HRSV F; IgG; kinetic exclusion assay; minimal biotinylation; monoclonal antibodies; sensor surface density

Indexed keywords

IMMOBILIZED PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS FUSION PROTEIN;

ANIMAL; ANTIBODY AFFINITY; ARTICLE; BIOTINYLATION; CHEMISTRY; HUMAN; IMMUNOLOGY; KINETICS; MOUSE; PEPTIDE LIBRARY; PH; PROTEIN BINDING; PROTEIN QUATERNARY STRUCTURE; PROTEIN SECONDARY STRUCTURE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; BIOTINYLATION; HUMANS; HYDROGEN-ION CONCENTRATION; IMMOBILIZED PROTEINS; IMMUNOGLOBULIN FAB FRAGMENTS; KINETICS; MICE; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, SECONDARY; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VIRAL FUSION PROTEINS;

HUMAN RESPIRATORY SYNCYTIAL VIRUS; HYDRANGEA RINGSPOT VIRUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 84858273630     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.2149     Document Type: Article

References (42)

1. Abdiche YN, Malashock DS, Pons J,. 2008. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci. 17 (8): 1326-1335.
2. Arbiza J, Taylor G, Lopez JA, Furze J, Wyld S, Whyte P, Stott EJ, Wertz G, Sullender W, Trudel M, Melero JA,. 1992. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J. Gen. Virol. 73 (Pt 9): 2225-2234.
3. Beeler JA, van Wyke Coelingh K,. 1989. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J. Virol. 63 (7): 2941-2950. (Pubitemid 19156013)
4. Begoña Ruiz-Argüello M, González-Reyes L, Calder LJ, Palomo C, Martín D, Saíz MJ, García-Barreno B, Skehel JJ, Melero JA,. 2002. Effect of Proteolytic Processing at Two Distinct Sites on Shape and Aggregation of an Anchorless Fusion Protein of Human Respiratory Syncytial Virus and Fate of the Intervening Segment. Virology 298 (2): 317-326. (Pubitemid 35034547)
5. Calder LJ, Gonzalez-Reyes L, Garcia-Barreno B, Wharton SA, Skehel JJ, Wiley DC, Melero JA,. 2000. Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology 271 (1): 122-131. (Pubitemid 30341521)
6. Cannon MJ, Openshaw PJ, Askonas BA,. 1988 Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J. Exp. Med. 168 (3): 1163-1168.
7. Canziani GA, Klakamp S, Myszka DG,. 2004. Kinetic screening of antibodies from crude hybridoma samples using Biacore. Anal. Biochem. 325 (2): 301-307. (Pubitemid 38134367)
8. Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin A, Lam SK, Ksiazek TG, Rollin PE, Zaki SR, Shieh WJ, Goldsmith CS, Gubler DJ, Roehrig JT, Eaton B, Gould AR, Olson J, Field H, Daniels P, Ling AE, Peters CJ, Anderson LJ, Mahy BW,. 2000. Nipah Virus: A Recently Emergent Deadly Paramyxovirus. Science 288 (5470): 1432-1435. (Pubitemid 30366331)
9. Darling RJ, Brault PA,. 2004. Kinetic exclusion assay technology: characterization of molecular interactions. Assay Drug Dev. Technol. 2 (6): 647-657. (Pubitemid 40309424)
10. Day N, Branigan P, Liu C, Gutshall L, Luo J, Melero J, Sarisky R, Del Vecchio A,. 2006. Contribution of cysteine residues in the extracellular domain of the F protein of human respiratory syncytial virus to its function. Virol. J. 3 (1): 34.
11. Drake AW, Myszka DG, Klakamp SL,. 2004. Characterizing high-affinity antigen/antibody complexes by kinetic- and equilibrium-based methods. Anal. Biochem. 328 (1): 35-43. (Pubitemid 38479615)
12. Enders G, 1996. Paramyxoviruses. In:, Baron S, (ed). Medical Microbiology. 4th ed. University of Texas Medical Branch at Galveston: Galveston (TX).
13. Hermanson GT,. 2008. Bioconjugate Techniques. Academic Press, Inc.
14. Jonsson U, Fagerstam L, Ivarsson B, Johnsson B, Karlsson R, Lundh K, Lofas S, Persson B, Roos H, Ronnberg I, Sjölander S, Stahlberg R, Urbaiczky C, Östlin H, Malmquist M,. 1991. Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. Biotechniques 11 (5): 620-627.
15. Jonsson U, Malmqvist M,. 1992. Real time biospecific interaction analysis. JAI press: Advances in Biosensors, 291-336.
16. Karlsson R, Katsamba PS, Nordin H, Pol E, Myszka DG,. 2006. Analyzing a kinetic titration series using affinity biosensors. Anal. Biochem. 349 (1): 136-147. (Pubitemid 43129567)
17. Katsamba PS, Navratilova I, Calderon-Cacia M, Fan L, Thornton K, Zhu M, Bos TV, Forte C, Friend D, Laird-Offringa I, Tavares G, Whatley J, Shi E, Widom A, Lindquist KC, Klakamp S, Drake A, Bohmann D, Roell M, Rose L, Dorocke J, Roth B, Luginbühl B, Myszka DG,. 2006. Kinetic analysis of a high-affinity antibody/antigen interaction performed by multiple Biacore users. Anal. Biochem. 352 (2): 208-221.
18. Klein JS, Gnanapragasam PN, Galimidi RP, Foglesong CP, West AP, Jr., Bjorkman PJ,. 2009. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc. Natl. Acad. Sci. U. S. A. 106 (18): 7385-7390.
19. Klein JS, Bjorkman PJ,. 2010. Few and Far Between: How HIV May Be Evading Antibody Avidity. PLoS Pathog. 6 (5): e1000908.
20. Knock SL, Miller BT, Blankenship JE, Nagle GT, Smith JS, Kurosky A,. 1991. N-acylation of Aplysia egg-laying hormone with biotin. Characterization of bioactive and inactive derivatives. J Biol Chem 266 (36): 24413-24419. (Pubitemid 21908957)
21. Liu C, Day ND, Branigan PJ, Gutshall LL, Sarisky RT, Del Vecchio AM,. 2007. Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus. Virol. J. 4: 71.
22. Magro M, Andreu D, Gomez-Puertas P, Melero JA, Palomo C,. 2010. Neutralization of Human Respiratory Syncytial Virus Infectivity by Antibodies and Low-Molecular-Weight Compounds Targeted against the Fusion Glycoprotein. J. Virol. 84 (16): 7970-7982.
23. Martin D, Calder LJ, Garcia-Barreno B, Skehel JJ, Melero JA,. 2006. Sequence elements of the fusion peptide of human respiratory syncytial virus fusion protein required for activity. J. Gen. Virol. 87 (6): 1649-1658. (Pubitemid 43827219)
24. McLellan JS, Yang Y, Graham BS, Kwong PD,. 2011. Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes. J. Virol. 85 (15): 7788-7796.
25. McLellan JS, Chen M, Chang J-S, Yang Y, Kim A, Graham BS, Kwong PD,. 2010a. Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex with Neutralizing Antibody 101F. J. Virol. 84 (23): 12236-12244.
26. McLellan JS, Chen M, Kim A, Yang Y, Graham BS, Kwong PD,. 2010b. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat. Struct. Mol. Biol. 17 (2): 248-250.
27. Muzykantov VR, Gavriluk VD, Reinecke A, Atochina EN, Kuo A, Barnathan ES, Fisher AB,. 1995. The functional effects of biotinylation of anti->angiotensin-converting enzyme monoclonal antibody in terms of targeting in vivo. Anal. Biochem. 226 (2): 279-287.
28. Myszka DG,. 1999. Improving biosensor analysis. J. Mol. Recognit. 12 (5): 279-284. (Pubitemid 129708590)
29. Myszka DG, Morton TA,. 1998. CLAMP: a biosensor kinetic data analysis program. Trends Biochem. Sci. 23 (4): 149-150.
30. Önell A, Andersson K,. 2005. Kinetic determinations of molecular interactions using Biacore-minimum data requirements for efficient experimental design. J. Mol. Recognit. 18 (4): 307-317. (Pubitemid 41059727)
31. Papalia G, Myszka D,. 2010. Exploring minimal biotinylation conditions for biosensor analysis using capture chips. Anal. Biochem. 403 (1-2): 30-35.
32. Ruiz-Arguello MB, Martin D, Wharton SA, Calder LJ, Martin SR, Cano O, Calero M, Garcia-Barreno B, Skehel JJ, Melero JA,. 2004. Thermostability of the human respiratory syncytial virus fusion protein before and after activation: implications for the membrane-fusion mechanism. J. Gen. Virol. 85 (12): 3677-3687. (Pubitemid 39591875)
33. Schofield DJ, Stephenson JR, Dimmock NJ,. 1997. Variations in the neutralizing and haemagglutination-inhibiting activities of five influenza A virus-specific IgGs and their antibody fragments. J. Gen. Virol. 78 (10): 2431-2439. (Pubitemid 27469983)
34. Smith BJ, Lawrence MC, Colman PM,. 2002. Modelling the structure of the fusion protein from human respiratory syncytial virus. Protein Eng. 15 (5): 365-371. (Pubitemid 34601728)
35. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, Dormitzer PR, Carfi A,. 2011. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc. Natl. Acad. Sci. 108 (23): 9619-9624.
36. Tao Y, Nishikawa S, Nomura M, Kitabatake N, Tani F,. 2005. Biotinylation of heat shock protein 70 induces RANTES production in HEK293 cells in a CD40-independent pathway. Biochem. Biophys. Res. Commun. 338 (2): 700-709. (Pubitemid 41597700)
37. Tornetta M, Baker S, Whitaker B, Lu J, Chen Q, Pisors E, Shi L, Luo J, Sweet R, Tsui P,. 2010. Antibody Fab display and selection through fusion to the pIX coat protein of filamentous phage. J. Immunol. Methods 360 (1-2): 39-46.
38. Wu H, Pfarr DS, Tang Y, An LL, Patel NK, Watkins JD, Huse WD, Kiener PA, Young JF,. 2005. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J. Mol. Biol. 350 (1): 126-144. (Pubitemid 40804737)
39. Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA,. 2007a. Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract. J. Mol. Biol. 368 (3): 652-665. (Pubitemid 46527610)
40. Wu SJ, Schmidt A, Beil EJ, Day ND, Branigan PJ, Liu C, Gutshall LL, Palomo C, Furze J, Taylor G, Melero JA, Tsui P, Del Vecchio AM, Kruszynski M,. 2007b. Characterization of the epitope for anti-human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches. J. Gen. Virol. 88 (Pt 10): 2719-2723. (Pubitemid 47555025)
41. Yin HS, Wen X, Paterson RG, Lamb RA, Jardetzky TS,. 2006. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 439 (7072): 38-44. (Pubitemid 43053622)
42. Zeder-Lutz G, Benito A, Van Regenmortel MH,. 1999. Active concentration measurements of recombinant biomolecules using biosensor technology. J. Mol. Recognit. 12 (5): 300-309. (Pubitemid 129708593)